2023年1月6日

风险资本新闻|私人股本风险资本目录|私人股本目录风险资本公司列表/风险资本和私人股本公司和出版来源自1998年以来,VCPro数据库是最可靠的、最新的和负担得起的风险资本目录2022最新更新版现在可用!(2022年7月更新)VCPro数据库2022年25日版-一个可下载的和可搜索的数据库与风险资本6800 +全球风险资本和私人股本公司。最可靠的、最新的和负担得起的风险资本的目录。VCPro数据库可以在Windows和macOS版本。自1998年以来,它已经出版。Onc.AIRaises $25 Million Series A Financing Co-Led by MassMutual and Action Potential Venture Capital Financing will support commercialization of a novel digital clinical management solution focused on immuno-oncology therapies SAN CARLOS, Calif. & WATERLOO, Ontario, January 5, 2023-- Onc.AI, a medical technology company developing a novel digital clinical management solution focused on immuno-oncology, announced today it has closed a $25 million Series A financing co-led by MassMutual and Action Potential Venture Capital (a GSK venture fund). Also participating were Life Extension Ventures and all existing investors including Blue Venture Fund, Accomplice, Digitalis Ventures, and KdT Ventures. “Having first learned about Onc.AI through a leading precision-oncology expert, we are thrilled to partner with an exceptional team and help the company as they aim to serve medical oncologists and cancer patients broadly,” said David Diaz-Casariego, Portfolio Manager of Alternative Investments at MassMutual. New investor Action Potential Venture Capital invests in companies advancing the fields of bioelectronic medicines, and enabling technologies for precision medicine. “Onc.AI’s novel platform, which leverages radiomics and deep learning, has the potential to improve medical oncologist clinical decision-making and to meaningfully advance pharma immuno-oncology research and clinical trials,” said Juan-Pablo Mas of Action Potential Venture Capital (APVC). “APVC is excited to support the team’s efforts in establishing a leadership position in this emerging category.” In conjunction with the financing, David Diaz-Casariego and Juan-Pablo Mas will join the Onc.AI Board of Directors alongside Dr. Emir Sandhu (Blue Venture Fund), Dr. Julie Hambleton (Independent Director), Jonathan Fleming (Board Chair) and Akshay Nanduri. “In just two years, Onc.AI has assembled a market leading real-world data asset focused on immuno-oncology which has enabled the development of a powerful suite of AI models to assist medical oncologists in clinical decision-making,” said Akshay Nanduri, Co-founder and CEO of Onc.AI. “On behalf of the company and existing investors, I would like to welcome MassMutual Alternative Investments and Action Potential Venture Capital as we work together to improve oncology clinical management in a significant way. This major financing will be allocated to achieving the necessary development and regulatory milestones preceding commercialization of our first product in lung cancer. Proceeds will also be used to support our currently active and future research collaborations with global pharmaceutical leaders.” About Onc.AI Onc.AI is a privately held medical technology company developing a digital clinical management platform focused on immuno-oncology. Onc.AI is backed by premier investment firms The Blue Venture Fund, MassMutual Alternative Investments, Action Potential Venture Capital, Accomplice, Digitalis Ventures, Life Extension Ventures, KdT Ventures as well as prominent individual investors who are leaders in Enterprise SaaS, AI/drug-discovery, precision/medical oncology, and radiology. For more information, visit http://onc.ai About MassMutual MassMutual is a leading mutual life insurance company that is run for the benefit of its members and participating policyowners. Founded in 1851, the company has been continually guided by one consistent purpose: we help people secure their future and protect the ones they love. With a focus on delivering long-term value, MassMutual offers a wide range of protection, accumulation, wealth management and retirement products and services. For more information, visit www.massmutual.com. About Action Potential Venture Capital Action Potential Venture Capital (APVC) is an independent corporate venture arm of GlaxoSmithKline (GSK). The firm invests globally in companies pursuing the development of bioelectronic medicines and enabling technologies for precision medicine. For more information about APVC visit www.actionpotentialvc.com. Contact: